Navigation Links
Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits

n the development and commercialisation of drugs for pain control, sedation and other CNS disorders such as Parkinson's disease. The company is based in Cambridge, England. For further information visit the CeNeS web site: www.cenes.com

About M6G Morphine formulations are the gold standard treatment for the relief of moderate to severe post-operative pain. A limitation of morphine treatment is often the unpleasant side effects experienced, of which nausea and vomiting are the most common. PONV is rated among patients as one of the most distressing after-effects of surgery and reduces their quality of life.

The active potent metabolite of morphine, morphine-6-glucuronide (M6G), may offer therapeutic advantages over morphine in having an equivalent analgesic effect, but with a reduced tendency to cause nausea, vomiting and respiratory depression. Phase II and III clinical trials have shown that M6G given intravenously produces equivalent analgesia to morphine to combat post-operative pain. Studies have also shown that M6G reduced the incidence of nausea and vomiting when compared directly with morphine. Other studies published recently in the scientific literature demonstrate that M6G also reduces respiratory depression compared to morphine.

M6G022 Study Design

The study involved 24 centres in six European countries and recruited 517 patients. The study was designed primarily to provide key information on a comparison of effective intravenous pain management regimens of M6G or morphine treatment for a minimum of 24 hours (and up to 48 hours) following major abdominal surgery. Morphine is generally accepted as the "gold standard" drug for use in these circumstances. Initial pain management was achieved by administration of a loading dose and titration of either M6G or morphine to achieve acceptably low levels of pain for the patient to go onto the ward. In the ward, pain management treatme
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
3. Phase III Clinical Trial with 4-Month Long-Acting Formulation of Triptorelin: Ipsen Decides Not to Perform Further Administration
4. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
5. Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical Trial Data
6. MIV Therapeutics Announces Pivotal Test Results Further Validating Company Stent Coatings Meet Critical FDA Fatigue Guidelines
7. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
8. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
9. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
10. Positive Statistical Analysis from Synthetic Bloods Oxycyte Traumatic Brain Injury Trial Indicates Achievement of Primary Endpoint
11. ISTA Pharmaceuticals Announces Statistically Significant Preliminary Results From its U.S. Phase II/III Clinical Study Of Bepotastine
Post Your Comments:
(Date:9/15/2014)... 2014 PDL BioPharma, Inc. (PDL) (NASDAQ: ... the September 12, 2014, regular quarterly dividend payment of $0.15 ... as of September 5, 2014, the record date. ... a portfolio of patents and royalty assets, consisting primarily ... license agreements with various biotechnology and pharmaceutical companies. PDL ...
(Date:9/15/2014)... Ill. , Sept. 15, 2014 ... equipment and information systems technology, announced today an ... This agreement is for Sysmex reagents, controls and ... pocH-100 i ™ , Sysmex XP-300™, XT-Series ... The agreement is effective immediately and continues until ...
(Date:9/15/2014)... VEGAS , Sept. 15, 2014  Dr. Navneet ... Las Vegas have recently announced their continued investment in cutting ... of patients treated at the Center and a national reputation ... paying off. In speaking with multiple cancer survivors who have ... is beloved for both his warm, friendly manner and his ...
Breaking Medicine Technology:PDL BioPharma Completes Regular Quarterly Dividend Payment 2Sysmex America, Inc. Renews LABSCO Distributorship 2Sysmex America, Inc. Renews LABSCO Distributorship 3Cancer Care Center Emphasizing Innovative Oncology Treatments 2
... THOUSAND OAKS, Calif., Sept. 14 Amgen (Nasdaq: ... Bank of America Merrill Lynch Global Healthcare Conference ... at 9:50 a.m. Greenwich Mean Time.  Amgen executives ... Willard Dere, M.D., senior vice president, International Chief ...
... Sept. 14 Praxis EMR has submitted its application to ... apply for HITECH certification in the country. Under the ARRA ... incentives if they can demonstrate "meaningful use" of a certified ... Department of Health and Human Services to test and certify ...
Cached Medicine Technology:Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference 2Praxis EMR Among First to Apply for HITECH Certification 2
(Date:9/16/2014)... (PRWEB) September 16, 2014 Magpi, a ... and communication applications, today announced that CEO and ... Count, a cross-sector ideation session focusing on the use ... in New York City on September 23. Dr. Selanikio ... data to provide insights on global health programming and ...
(Date:9/16/2014)... A recent article discusses the ... filler, “Expression”, which has not been approved for cosmetic ... be used as an intra-nasal splint following rhinoplasty, and ... a dermal filler. Because of its low cost, some ... and patients have had bad reactions to it including ...
(Date:9/16/2014)... Oakland, CA (PRWEB) September 16, 2014 ... double-issue journal on cancer and genetics in Cuba. ... and genetics, the two themes are intrinsically connected, since ... cancer-related articles relate to the full spectrum of cancer ... Cubans' shared ancestry is the topic of an ...
(Date:9/16/2014)... NY (PRWEB) September 16, 2014 On ... Champion Danielle Strassle at the 2014 Buffalo Bills Alumni ... Buffalo, NY. , Bills legend and NFL Hall-of-Famer ... assisted the foundation in honoring Strassle for her dedication ... professional goals and inspire others in her community to ...
(Date:9/16/2014)... Online retailer Kettlebell Kings has announced that ... kettlebell purchases in their online store. The company wants ... with this effective workout method that is quickly gaining ... carries a variety of kettlebell brands as well as ... , “We’ve seen for ourselves how effective kettlebells ...
Breaking Medicine News(10 mins):Health News:Magpi CEO and Co-founder Dr. Joel Selanikio to Speak at Health Workers Count, Global Health Session Held during the UN General Assembly 2Health News:FDA Warns Against Non-approved Dermal Filler 2Health News:FDA Warns Against Non-approved Dermal Filler 3Health News:MEDICC Review Journal Dedicates Double Issue to Cancer and Genetics 2Health News:MEDICC Review Journal Dedicates Double Issue to Cancer and Genetics 3Health News:The HearStrong Foundation and the Buffalo Bills Alumni Foundation Celebrated HearStrong Champion During 2014 Alumni Weekend 2Health News:Join the Kettlebell Movement - Kettlebell Kings Announces $0 Shipping on all Orders 2
... French . Robot-assisted surgery dramatically improves outcomes ... researchers at the Jewish General Hospital,s Lady Davis Institute ... post-operative complications and shorter hospital stays, robotic procedures also ... late 2010 in a series of studies in ...
... , WEDNESDAY, Jan. 12 (HealthDay News) -- People who have ... after receiving the results, whether they are positive or negative, ... or get screening tests that might modify that risk, despite ... in the Jan. 13 issue of the New England ...
... of Science (AAAS) has elevated four Dartmouth professors to the ... Dartmouth Medical School. Medical School faculty members Charles ... MD, join Dartmouth biologist C. Robertson McClung among the 504 ... eight other Dartmouth researchers to have earned the distinction. ...
... Jan. 12 (HealthDay News) -- Research in rats suggests that ... by persistent ringing or other noises in the ears. ... a result of hearing loss. In this study, U.S. ... variety of sound tones over an extended period of time. ...
... cancer with a relatively high degree of accuracy when applied ... cancer, according to a study in the January issue of ... was performed at the University of Washington and Seattle Cancer ... with 592 patients who were recently diagnosed with breast cancer ...
... Scientists are reporting a scientific basis for the long-standing belief ... other countries can prevent and treat cataracts, a clouding of ... of vision loss worldwide. Their study appears in Inorganic ... Wu, Fu-Yung Huang, Shih-Hsiung Wu and colleagues note that eye ...
Cached Medicine News:Health News:Robotic surgery of 'tremendous benefit' to patients, say JGH researchers 2Health News:Consumer Genetic Testing May Not Boost Users' Anxiety 2Health News:Consumer Genetic Testing May Not Boost Users' Anxiety 3Health News:Dartmouth Medical School faculty named fellows of the American Association for the Advancement of Science 2Health News:Animal Study Finds Nerve Stimulation May Thwart Tinnitus 2
The original battery-operated suction and irrigation system features a new ergonomic hand piece and superior performance characteristics that have increased the overall flow rate....
... Bringing together the best of both ... intraocular instrument is the latest addition ... lightweight Eraser bipolar cautery instruments for ... hemostasis with extrusion aspiration and backflush ...
...
...
Medicine Products: